Nifedipine Medication Market, By Dosage Form, By Indication, By Distribution Channel, By Geography
상품코드:1741201
리서치사:Coherent Market Insights
발행일:2025년 03월
페이지 정보:영문
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
세계의 니페디핀 시장은 2025년 12억 5,670만 달러로 추정되고, 2032년까지 23억 5,700만 달러에 이를 것으로 예측되고, 2025년부터 2032년까지 연평균 성장률(CAGR) 9.4%를 보일 것으로 예측됩니다.
보고 범위
보고서 세부정보
기준연도
2024년
2025년 시장 규모
12억 5,670만 달러
실적 데이터
2020-2024년
예측 기간
2025-2032년
예측 기간: 2025-2032년 CAGR
9.40%
2032년 금액 예측
23억 5,700만 달러
니페디핀은 칼슘 채널 차단제로 고혈압이나 협심증에 의한 흉통의 치료에 사용됩니다. 니페디핀은 심장이나 동맥의 근육세포에 있는 칼슘 채널을 차단하는 것으로 작용합니다. 이것에 의해 혈관이 확대되어, 혈압이 저하해, 심장에 대한 부담이 경감됩니다.
시장 역학
고혈압과 심혈관 질환을 앓고 있는 사람들 증가와 고령화 인구 증가는 예측 기간 동안 세계 니페디핀 약물 시장의 성장을 가속할 것으로 예상되는 주요 요인입니다.
게다가, 시장 진출기업은 니페디핀의 신제품 출시에 이르렀으며, 이는 예측 기간동안 세계 니페디핀 시장의 성장을 증가시킬 것으로 예측됩니다. 예를 들어, 2019년 9월 18일, 제네릭 의약품 개발 기업인 AVET Pharmaceuticals는 니페디핀 소프트젤 캡슐을 출시했습니다. 이 제품은 10mg과 20mg의 효능으로 쉽게 구할 수 있습니다. 이 제품은 칼슘 채널 차단제 프로카르디아의 AB 랭크의 제네릭 의약품이며, 아벳사의 견고한 제네릭 경구 고형 제제 포트폴리오에 가입하고 있습니다.
그러나 특허 만료, 규제 문제, 부작용, 대체 치료의 가용성, 치료 패러다임 전환, 가격 압력 등은 예측 기간 동안 세계 니페디핀 약물 시장의 성장을 방해할 것으로 예측됩니다.
본 조사의 주요 특징
본 보고서에서는 세계의 니페디핀 시장을 상세하게 분석하여 2024년을 기준연도로 한 예측기간(2025-2032년) 시장 규모와 복합연간 성장률(CAGR)을 제공합니다.
또한 다양한 부문에 걸친 잠재적인 수익 기회를 밝히고 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
또한 시장 성장 촉진요인, 억제요인, 기회, 신제품의 상시와 승인, 시장 동향, 지역에 의한 전망, 주요 기업이 채용하는 경쟁 전략 등에 관한 주요 고찰도 제공합니다.
기업 하이라이트, 제품 포트폴리오, 주요 하이라이트, 재무 실적, 전략 등 다음 매개변수를 기반으로 세계 니페디핀 시장의 주요 기업을 프로파일링합니다.
이 보고서로부터 통찰은 마케팅 담당자나 기업의 경영진이, 장래의 제품의 발매, 유형의 업그레이드, 시장 확대, 마케팅 전술에 관한 정보에 근거한 의사 결정을 실시하는 것을 가능하게 한다고 생각됩니다.
세계의 니페디핀 시장 보고서는 투자자, 공급자, 제품 제조업체, 유통업체, 신규 참가자, 재무 애널리스트 등, 이 산업의 다양한 이해 관계자에 대응하고 있습니다.
이해관계자는 세계의 니페디핀 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 용이하게 할 수 있습니다.
목차
제1장 조사의 목적과 전제조건
조사 목적
전제조건
약어
제2장 시장 전망
보고서 설명
시장 정의와 범위
주요 요약
Coherent Opportunity Map (COM)
제3장 시장 역학, 규제, 동향 분석
시장 역학
성장 촉진요인
억제요인
기회
규제 시나리오
제품 출시/승인
PEST 분석
Porter's Five Forces 분석
합병, 인수, 제휴
제4장 세계의 니페디핀 시장 - 코로나 바이러스(COVID-19) 팬데믹의 영향
COVID-19 역학
공급측과 수요측의 분석
경제에 미치는 영향
제5장 세계의 니페디핀 시장 : 제형별, 2020-2032년
소개
정제
서방정
캡슐
기타(설하정 및 스프레이, 패치 등)
제6장 세계의 니페디핀 시장 : 적응증별, 2020-2032년
소개
고혈압
협심증
레이노 현상
기타(조산, 혈관 경련성 질환 등)
제7장 세계의 니페디핀 시장 : 유통 채널별, 2020-2032년
소개
병원 약국
소매 약국
온라인 약국
제8장 세계의 니페디핀 시장 : 지역별, 2020-2032년
소개
북미
미국
캐나다
라틴아메리카
브라질
아르헨티나
멕시코
기타 라틴아메리카
유럽
독일
영국
스페인
프랑스
이탈리아
러시아
기타 유럽
아시아태평양
중국
인도
일본
호주
한국
ASEAN 국가
기타 아시아태평양
중동
GCC 국가
이스라엘
기타 중동
아프리카
남아프리카
북아프리카
중앙 아프리카
제9장 경쟁 구도
기업 프로파일
Pfizer Inc
Novartis AG
Merck & Co., Inc.
AstraZeneca PLC
Teva Pharmaceutical Industries Ltd
Mylan NV
Sanofi SA
Johnson & Johnson
GlaxoSmithKline plc.
Lupin Limited
Sun Pharmaceutical Industries Ltd.
Sandoz International GmbH(Novartis의 부문)
Dr. Reddy's Laboratories Ltd.
Torrent Pharmaceuticals Ltd.
Apotex Inc.
제10장 섹션
참고문헌
조사 방법
출판사에 대해
JHS
영문 목차
영문목차
Nifedipine Medication Market is estimated to be valued at USD 1,256.7 Mn in 2025 and is expected to reach USD 2,357.0 Mn by 2032, growing at a compound annual growth rate (CAGR) of 9.4% from 2025 to 2032.
Report Coverage
Report Details
Base Year:
2024
Market Size in 2025:
USD 1,256.7 Mn
Historical Data for:
2020 To 2024
Forecast Period:
2025 To 2032
Forecast Period 2025 to 2032 CAGR:
9.40%
2032 Value Projection:
USD 2,357.0 Mn
Nifedipine is a calcium channel blocker medication which is used for treating high blood pressure and chest pain caused by angina. Calcium channel blockers work by relaxing muscles in artery walls and increasing the supply of blood and oxygen to the heart. Nifedipine was first approved for medical use in 1983. It works by blocking calcium channels in heart and artery muscle cells. This helps blood vessels dilate, thus lowering blood pressure and reducing strain on the heart. It comes in both short-acting and long-acting tablet formulations and has proven effective for millions worldwide in controlling blood pressure and reducing chest pain.
Market Dynamics:
A growing number of people suffering from hypertension and cardiovascular illnesses and increasing aging population are major factors expected to drive growth of the global nifedipine medication market during the forecast period.
Moreover, market players are indulged in launching new products for nifedipine and this is expected to increase the growth of the global nifedipine market, over the forecast period. For instance, on September 18, 2019, AVET Pharmaceuticals, a developer of generic medicines, launched nifedipine soft gel capsules. The products was being readily available in the potency of 10 and 20mg. This product is the AB-rated generic equivalent to the calcium blocker drug Procardia and adds to Avet's robust portfolio of generic oral solid products.
However, patent expiration, regulatory challenges, adverse effects, availability of alternative treatments, shifting treatment paradigms, pricing pressures are expected to hamper the growth of the global nifedipine medication market over the forecast period.
Key features of the study:
This report provides in-depth analysis of the global nifedipine medication market, and provides market size (US$ Mn) and compound annual growth rate (CAGR %) for the forecast period (2025-2032), considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global nifedipine medication market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Pfizer Inc., Novartis AG, Merck & Co., Inc., AstraZeneca PLC, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sanofi S.A., Johnson & Johnson, GlaxoSmithKline plc, Lupin Limited , Sun Pharmaceutical Industries Ltd., Sandoz International GmbH (a Novartis division) Dr. Reddy's Laboratories Ltd., Torrent Pharmaceuticals Ltd, and Apotex
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global nifedipine medication market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global nifedipine medication market
Global Nifedipine Medication Market Detailed Segmentation:
By Dosage Form:
Tablets
Extended-release Tablets
Capsules
Others (Sublingual tablets/spray, Patches and Others)
By Indication:
Hypertension
Angina Pectoris
Raynaud's Phenomenon
Others (Pre-term labor, vasospastic conditions and Others)
By Distribution Channel:
Hospitals Pharmacies
Retail Pharmacies
Online Pharmacies
By Region:
North America
Europe
Asia Pacific
Latin America
Middle East and Africa
Company Profiles:
Pfizer Inc.
Novartis AG
Merck & Co., Inc.
AstraZeneca PLC
Teva Pharmaceutical Industries Ltd.
Mylan N.V.
Sanofi S.A.
Johnson & Johnson
GlaxoSmithKline plc
Lupin Limited
Sun Pharmaceutical Industries Ltd.
Sandoz International GmbH (a Novartis division)
Dr. Reddy's Laboratories Ltd.
Torrent Pharmaceuticals Ltd.
Apotex Inc.
Table of Contents
1. Research Objectives and Assumptions
Research Objectives
Assumptions
Abbreviations
2. Market Purview
Report Description
Market Definition and Scope
Executive Summary
Market Snippet, By Dosage Form
Market Snippet, By Indication
Market Snippet, By Distribution Channel
Market Snippet, By Region
Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
Market Dynamics
Drivers
Restraints
Opportunities
Key Highlights
Regulatory Scenario
Recent Trends
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Mergers, Acquisitions, and Collaborations
4. Global Nifedipine Medication Market - Impact of Coronavirus (COVID-19) Pandemic
COVID-19 Epidemiology
Supply Side and Demand Side Analysis
Economic Impact
5. Global Nifedipine Medication Market, By Dosage Form, 2020-2032, (US$ Mn)
Introduction
Market Share Analysis, 2025 and 2032 (%)
Y-o-Y Growth Analysis, 2021 - 2032
Segment Trends
Tablets
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
Extended-Release Tablets
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
Capsules
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
Others (Sublingual tablets/spray, Patches and Others)
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
6. Global Nifedipine Medication Market, By Indication, 2020-2032, (US$ Mn)
Introduction
Market Share Analysis, 2025 and 2032 (%)
Y-o-Y Growth Analysis, 2021 - 2032
Segment Trends
Hypertension
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
Angina Pectoris
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
Raynaud's Phenomenon
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
Others (Pre-term labor, vasospastic conditions and Others)
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
7. Global Nifedipine Medication Market, By Distribution Channel, 2020-2032, (US$ Mn)
Introduction
Market Share Analysis, 2025 and 2032 (%)
Y-o-Y Growth Analysis, 2021 - 2032
Segment Trends
Hospital Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
Retail Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
Online Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
8. 8. Global Nifedipine Medication Market, By Region, 2020-2032, (US$ Mn)
Introduction
Market Share Analysis, By Sub-region, 2025 and 2032 (%)
Y-o-Y Growth Analysis, For Sub-region, 2021 -2032
Segment Trends
North America
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2020-2032,(US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
U.S.
Canada
Latin America
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2020-2032,(US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
Brazil
Argentina
Mexico
Rest of Latin America
Europe
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2020-2032,(US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
Germany
U.K.
Spain
France
Italy
Russia
Rest of Europe
Asia Pacific
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2020-2032,(US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2020-2032,(US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Country/Sub-region, 2020-2032,(US$ Mn)
GCC
Israel
Rest of Middle East
Africa
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Dosage Form, 2020-2032,(US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Country/Sub-region, 2020-2032,(US$ Mn)
South Africa
North Africa
Central Africa
9. Competitive Landscape
Company Profile
Pfizer Inc
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Novartis AG
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Merck & Co., Inc.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
AstraZeneca PLC
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Teva Pharmaceutical Industries Ltd
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Mylan N.V.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Sanofi S.A.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Johnson & Johnson
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
GlaxoSmithKline plc.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Lupin Limited
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Sun Pharmaceutical Industries Ltd.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Sandoz International GmbH (a Novartis division)
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Dr. Reddy's Laboratories Ltd.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Torrent Pharmaceuticals Ltd.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Apotex Inc.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Analyst Views
10. Section
References
Research Methodology
About us
(주)글로벌인포메이션02-2025-2992kr-info@giikorea.co.kr ⓒ Copyright Global Information, Inc. All rights reserved.
